In cancer cells, metformin stimulates AMPK, with the inhibition of the mammalian target of rapamycin (mTOR)/ribosomal S6 kinase pathway and inhibition of pathological cell cycle progression, cell growth and angiogenesis [3, 4]. This evidence concerns the gene MTOR and cancer.